The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly

被引:0
作者
Ulahannan, Danny [1 ]
Wagg, Adrian [1 ]
机构
[1] Univ Coll London Hosp, Dept Geriatr Med, London WC1E 6AU, England
关键词
overactive bladder; tolterodine; urgency incontinence; URINARY-TRACT SYMPTOMS; QUALITY-OF-LIFE; ANTIMUSCARINIC AGENTS; POSTMENOPAUSAL WOMEN; OXYBUTYNIN; INCONTINENCE; TOLERABILITY; PLACEBO; SOLIFENACIN; DETRUSOR;
D O I
暂无
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 36 条
[1]  
Abrams P, 1998, BRIT J UROL, V81, P801
[2]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[3]  
Abrams P, 2000, AM J MANAG CARE, V6, pS580
[4]   Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder [J].
Anderson, Rodney U. ;
MacDiarmid, Scott ;
Kell, Sherron ;
Barada, James H. ;
Serels, Scott ;
Goldberg, Roger P. .
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2006, 17 (05) :502-511
[5]   LUTS treatment: Future treatment options [J].
Andersson, K.-E. .
NEUROUROLOGY AND URODYNAMICS, 2007, 26 (06) :934-947
[6]   Mechanisms of disease: Central nervous system involvement in overactive bladder syndrome [J].
Andersson, Karl-Erik .
NATURE CLINICAL PRACTICE UROLOGY, 2004, 1 (02) :103-108
[7]   Urinary incontinence: Does it increase risk for falls and fractures? [J].
Brown, JS ;
Vittinghoff, E ;
Wyman, JF ;
Stone, KL ;
Nevitt, MC ;
Ensrud, KE ;
Grady, D .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (07) :721-725
[8]  
Caulfield MP, 1998, PHARMACOL REV, V50, P279
[9]   A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial [J].
Chapple, CR ;
Martinez-Garcia, R ;
Selvaggi, L ;
Toozs-Hobson, P ;
Warnack, W ;
Drogendijk, T ;
Wright, DM ;
Bolodeoku, J .
EUROPEAN UROLOGY, 2005, 48 (03) :464-470
[10]   Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder [J].
Chapple, CR ;
Rechberger, T ;
Al-Shukri, S ;
Meffan, P ;
Everaert, K ;
Huang, M ;
Ridder, A .
BJU INTERNATIONAL, 2004, 93 (03) :303-310